Key result
In vivo administration of selective substrate-based inhibitors of mammalian DDAH increased plasma ADMA levels, providing proof of concept for their physiological effects.
Answers are grounded in this paper and cite their sources.
The development of the first selective, reversible DDAH inhibitors provides a novel tool to probe the physiological effects of DDAH inhibition and a potential therapeutic approach for diseases with excess NO production.
The enzyme DDAH metabolizes methylarginines that are inhibitors of nitric oxide synthase (NOS). Substrate-based inhibitors of mammalian DDAH have been synthesized, with optimization to give selective inhibition of DDAH with no significant direct effect on NOSs. These are the first examples of reversible DDAH inhibitors with significant activity and selectivity. In vivo administration increases plasma ADMA levels, giving proof of concept that these inhibitors can be used to probe the physiological effects of DDAH inhibition, with potential for pharmaceutical use of DDAH inhibitors in diseases where excess NO production is implicated.
No takes yet. Share an insight, caveat, or question.
Rossiter et al. (2005) studied this question. Substrate-based inhibitors of mammalian DDAH was evaluated on Plasma ADMA levels. In vivo administration of selective substrate-based inhibitors of mammalian DDAH increased plasma ADMA levels, providing proof of concept for their physiological effects.
Synapse has enriched 10 related papers. Consider them for comparative context: